

acceptable adjuvants or additives.

GB
33. A peptide fragment having the amino acid sequence ANP(109-120), and derivatives thereof which are modified by protecting groups.--

REMARKS

Reconsideration and withdrawal of the rejections made in the June 23, 1999 Office Action is respectfully requested in view of the above amendments and the following remarks.

The Office Action indicates that the specification should be amended to reflect the status of the parent application. The specification has been amended as requested. In addition, the specification has been amended to include a section providing a brief description of the drawings.

Claim 1 was rejected under the judicially created doctrine of obviousness-type double patenting as unpatentable over claim 1 of U.S. Patent No. 5,767,239. Claim 1 has been canceled and new claims added to the application which are not directed to the process recited in claim 1 of U.S. Patent No. 5,767,239. In view of the cancellation of claim 1 and the addition of new claims to the application, applicants request that this rejection be withdrawn.

Claim 1 was rejected under 35 USC §112, second paragraph, as indefinite. As discussed above, claim 1 has been canceled and new claims added to the application. The new claims do not include the language found indefinite. In view of the cancellation of claim 1 and the addition of new claims to the application, applicants request that this

rejection be withdrawn.

In the event this paper is not timely filed, applicants hereby petition for an appropriate extension of time. The fee for this extension may be charged to our Deposit Account No. 14-1060, along with any other additional fees which may be required with respect to this paper.

Respectfully submitted,

NIKAIDO, MARMELSTEIN, MURRAY & ORAM LLP



Monica Chin Kitts
Attorney for Applicants
Registration No. 36,105

Atty. Docket No. P8341-8019
Metropolitan Square
655 Fifteenth Street, N.W.
Suite 330 - G Street Lobby
Washington, D.C. 20005-5701
(202) 638-5000

MCK:mck